CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

VERU stock tilts upward after FDA approves prostate drug

By Andrew Knoll

20:24, 13 December 2021

Veru logo on computer screen
Veru Pharmaceuticals - Photo: Shutterstock

Veru, an oncology-focussed biopharmaceutical company, gained FDA approval for its treatment for urinary tract symptoms caused by an enlarged prostate, sparking a 14% jump in pre-market trading on Monday.

The drug, ENTADFI, combines two already-existing drugs into one pill that treats benign prostatic hyperplasia (BPH), while reducing adverse effects on sexual health.

By using the existing standard, Finasteride, in conjunction with another BPH treatment used more commonly to combat erectile dysfunction, Tadalafil, Veru touts ENTADFI as a means to increase treatment efficacy while diminishing undesired effects.

It was one of seven drugs that Veru had in its development pipeline, including three for prostate treatments.

“FDA approval of ENTADFI, a new treatment for BPH, is a significant execution milestone for Veru and an important step in expanding revenues from our commercial Sexual Health Division. We use these revenues to invest and advance our late clinical stage oncology drug pipeline portfolio as well as our global Phase 3 Covid clinical study,” said Mitchell Steiner, MD, chair, president and chief executive officer.

Distribution and commercialisation

Veru said it plans to commercialise ENTADFI early in the coming year, and that it has already begun coordinating distribution through at least two channels.

The company has its own direct-to-patient telemedicine platform, and it also has a partnership with GoodRX to reach its extensive network of patients and health-care providers.


15.33 Price
+1.200% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 22:00 (UTC)
Spread 0.19


240.95 Price
+0.360% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 22:00 (UTC)
Spread 0.19


7.07 Price
+0.140% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 22:00 (UTC)
Spread 0.04


470.65 Price
+0.830% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 22:00 (UTC)
Spread 0.22

“We are in the process of augmenting our marketing and sales efforts by adding commercialisation partners in the US and ex-US. We expect to begin commercialisation in early calendar year 2022. The treatment of BPH is an annual multi-billion-dollar market with over 45 million US prescriptions filled each year and is projected to continue to grow with an ageing male population,” Steiner said.

Market focus, market size

Veru focusses on treatments for breast cancer and prostate cancer. Those are the two most common types of cancer in the United States. Three of Veru’s remaining pipeline drugs are for breast cancer, two are for prostate cancer and the company is also developing a Covid-19 antiviral, anti-inflammatory drug.

The market for breast cancer treatments in 2020 was more than $20bn, with projections indicating that it could surpass $32bn in 2026. Prostate cancer treatments were assessed to have a total market value of $63bn in 2021, and that could approach $100bn in 2026.

“We are developing three drugs, VERU-111, VERU-100, and Zuclomiphene citrate, each of which addresses large potential markets relating to prostate cancer and prostate cancer supportive care,” according to the company.

Read more: AstraZeneca’s prostate cancer drug trial shows positive results

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading